In the News
Half of diabetics do not meet recommended care goals
Almost half of U.S. adults with diabetes did not meet recommended goals for diabetes care, despite improvements in controlling risk factors and adhering to preventive practices from 1999 to 2010, a study concluded.
New calculator predicts two-year mortality risk in type 2 diabetes
Researchers have developed a new Web-based calculator that predicts short-term mortality risk in patients with type 2 diabetes.
Aspirin therapy not associated with cardiovascular benefit in type 2 diabetes
Aspirin showed no cardiovascular benefit and may have been associated with worse outcomes in a recent study of patients with type 2 diabetes.
MKSAP Quiz: hypoglycemia unawareness
This month's quiz asks readers to evaluate a 33-year-old woman with multiple recent episodes of severe hypoglycemia.
Mortality, hospitalization may be similar with sitagliptin versus other oral antidiabetics
Sitagliptin was associated with similar rates of hospital admission and mortality as other glucose-lowering drugs, according to a recent study of patients with type 2 diabetes.
Consensus statement offers strategies for preventing hypoglycemia
Consequences of hypoglycemia and strategies to prevent this condition in patients with diabetes were discussed in a recent consensus statement from the American Diabetes Association (ADA) and The Endocrine Society.
Metformin appears safe for heart failure patients, analysis finds
Metformin appears to be a safe option for glycemic control in heart failure patients, according to a recent meta-analysis.
Patients with diabetes facing vision loss at ever-earlier ages
The growing problem of diabetic retinopathy in young people and the need for response by primary care clinicians are discussed in the April ACP Internist.
Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes
A meta-analysis included 67 randomized controlled trials comparing dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo or other oral antidiabetic agents.
Metformin reduced CV events compared with glipizide in patients with type 2 diabetes and CAD
A multicenter randomized controlled trial of Chinese patients with type 2 diabetes and coronary artery disease found that metformin reduced cardiovascular events more than glipizide at 5 years.
What do I need to tell my patients about hypoglycemia?
Some key messages should be given to patients about avoiding and treating hypoglycemia.
Single and combo diabetes drugs approved
Alogliptin (Nesina) and two new combination drugs (alogliptin and metformin hydrochloride [Kazano] and alogliptin and pioglitazone [Oseni]) were approved by the FDA to improve blood glucose control in adults with type 2 diabetes, along with diet and exercise.
Incretin mimetics' effects on pancreas under investigation
The FDA is investigating reports of possible increased risk of pancreatitis and precancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes.
Spotlight on bariatric surgery
Treatment of type 2 diabetes with bariatric surgery was discussed by several recent publications, including updated guidelines from a group of medical specialty organizations.